Roche

ROCHE NEWSROOM (895 press releases)

Advanced Filtering & Sorting Options:

Roche to Acquire Carmot Therapeutics for USD 2.7 Billion, Expanding Its Portfolio in Obesity Treatment

PRESS RELEASE -- 4, December 2023

(IN BRIEF) Roche, a leading pharmaceutical company, has announced its definitive merger agreement to acquire Carmot Therapeutics, a privately owned US-based company specializing in obesity treatment and related metabolic diseases. The acquisition includes Carmot’s portfolio of clinical stage subcutaneous and … Read the full press release

Roche Introduces Elecsys® HBeAg Quant Test for Accurate Hepatitis B Diagnosis and Monitoring

PRESS RELEASE -- 27, November 2023

(IN BRIEF) Roche has unveiled Elecsys® HBeAg quant, a new immunoassay designed to detect the presence and quantity of the hepatitis B e antigen (HBeAg) in human serum and plasma. This diagnostic tool simplifies the process for both clinicians and … Read the full press release

Roche Launches HEV Infection Detection Tests to Support Global Disease Management

PRESS RELEASE -- 17, November 2023

(IN BRIEF) Roche has introduced the Elecsys®Anti-HEV IgM and Elecsys Anti-HEV IgG immunoassays for detecting hepatitis E virus (HEV) infections in regions accepting the CE mark. These tests aim to assist clinicians in diagnosing the cause of patients’ symptoms, determining … Read the full press release

Roche’s Elecsys NfL Test for Multiple Sclerosis Earns Breakthrough Device Designation from FDA

PRESS RELEASE -- 9, November 2023

(IN BRIEF) Roche, a leading healthcare company, has announced that its Elecsys Neurofilament Light Chain (NfL) test for Multiple Sclerosis (MS) has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). The Elecsys NfL test is designed … Read the full press release

Pfizer and BioNTech Report Promising Results for mRNA-Based Combination Vaccine Against Influenza and COVID-19

PRESS RELEASE -- 27, October 2023

(IN BRIEF) Pfizer and BioNTech have announced positive topline results from a Phase 1/2 study of their mRNA-based combination vaccine program for influenza and COVID-19. The lead formulations showed robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains. … Read the full press release

BioNTech to Announce Q3 2023 Financial Results and Host Innovation Series

PRESS RELEASE -- 24, October 2023

(IN BRIEF) BioNTech SE is set to reveal its financial results for the third quarter of 2023 on November 6th, 2023. The company invites investors and the public to participate in a conference call and webcast at 8:00 a.m. ET … Read the full press release

BioNTech to Showcase Advances in Cancer Therapy at ESMO Congress 2023

PRESS RELEASE -- 17, October 2023

(IN BRIEF) BioNTech will be presenting updates on multiple programs across its oncology pipeline at the European Society for Molecular Oncology (ESMO) Congress 2023. These updates include data on investigational CAR-T and ex-vivo T cell therapies, a novel ADC (antibody-drug … Read the full press release